



## Pharmacokinetics and Clinical Practice of Monoclonal Antibodies

Guest Editors:

**Dr. Ricardo Nalda-Molina**

School of Pharmacy, Miguel  
Hernández University, 03550 San  
Juan de Alicante, Spain

**Prof. Dr. Patricio Más-Serrano**

School of Pharmacy, Miguel  
Hernández University, 03550 San  
Juan de Alicante, Spain

**Dr. Amelia Ramon-Lopez**

School of Pharmacy, Miguel  
Hernández University, 03550 San  
Juan de Alicante, Spain

Deadline for manuscript  
submissions:

**closed (28 February 2023)**

### Message from the Guest Editors

Dear Colleagues,

The use of monoclonal antibodies (mAb) in the clinical practice has grown in the last decade in different fields, such as oncology, autoimmune diseases, osteoporosis, immunosuppression, coagulopathies, among other conditions.

The mAb match all the requirements needed to include them in model-informed precision dosing programs, and the high cost of the treatments make the dose individualization even more interesting to consider in order to increase the efficiency. However, the pharmacokinetic of many of the mAb differs from the small molecules in different aspects, including target-mediated drug disposition, which makes the PK model development more challenging.

The objective of this Special Issue is to review the state-of-the-art of two aspects. First, the new PKPD modelling strategies in mAb, and how these models could help to design phase II and III in drug development. Second, the different approaches for mAb in the model-informed precision dosing adopted in the clinical practice.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma